flumazenil has been researched along with Labhart-Willi Syndrome in 1 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lucignani, G | 1 |
| Panzacchi, A | 1 |
| Bosio, L | 1 |
| Moresco, RM | 1 |
| Ravasi, L | 1 |
| Coppa, I | 1 |
| Chiumello, G | 1 |
| Frey, K | 1 |
| Koeppe, R | 1 |
| Fazio, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cross-Species Multi-Modal Neuroimaging to Investigate GABA Physiology in Fragile X Syndrome[NCT04308954] | Phase 1 | 17 participants (Actual) | Interventional | 2016-11-01 | Terminated (stopped due to Difficulty with patient recruitment due to COVID-19 pandemic) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for flumazenil and Labhart-Willi Syndrome
| Article | Year |
|---|---|
GABA A receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil.
Topics: Adult; Brain; Carbon Radioisotopes; Chromosome Deletion; Female; Flumazenil; GABA Modulators; Humans | 2004 |